Tanker update september 2016 - Bimco

Tanker update september 2016 - Bimco

Demand Lower growth rates for refinery throughput and drawdowns on swollen oil stocks has impacted the seaborne tanker market negatively. BIMCO expected this to happen. The refiners and traders, primarily in Asia, have reduced their appetite for crude oil as margins and profits have diminished. Global oil prices came down from a mid-2015 level around USD 60 per barrel to …

Read more.

---
Update og Nyhedsstrøm Exelixis

Update og Nyhedsstrøm Exelixis

Efter sin meget stærke Launch af Cabometyx er Exelixis blevet handlet til year-high i omegnen af 11,5-11,6, selv i den generelle makromodvind for markedet. Kursen afspejler flere ting, dels de meget stærke salgstal som var 2-3 gange højere end konsensus, dels at Updivo/Nivolumab har lidt tilbageslag og endeligt at man forleden annoncerede en malstrøm af præsentationer på ESMO, den europæiske pendant …

Read more.

---

DRY BULK SHIPPING: Poor freight rates despite strong demand growth from China

Demand The dry bulk commodity imports into and exports out of China we have seen in the first half of 2016 are very positive – and nothing short of extraordinary. But, putting it into perspective, compared to the devastating freight rate levels over the same period, it highlights that something is very wrong in the dry bulk market. The market is …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.